Aurobindo’s FY26 audited results are a formality. Profit growth is 0.6%.
The board approved audited numbers already public via a May press release. Consolidated PAT for the full year rose **0.6%** to **₹35,030 crore**.
— 5 earlier stories on Aurobindo Pharma Ltd. →What's new
- Board approved audited Q4 and FY26 results; numbers were already public via a prior May press release.
- Consolidated PAT: ₹9,208 cr in Q4 (+0.5% YoY), ₹35,030 cr for FY26 (+0.6% YoY).
- Routine auditor changes: secretarial auditors resigned, new ones appointed, internal auditors reappointed.
Why this matters
This is a compliance filing for numbers the market has already digested. The 0.6% full-year profit growth is negligible for a company of this scale, confirming a year of near-zero earnings momentum. The governance changes are procedural and add no new financial signal.
What we're watching
- FY27 guidance or commentary from management on growth drivers.
- Margin trends in the API and formulations businesses.
- Any new capital allocation plans announced alongside these audited results.
The full read
Aurobindo’s audited FY26 results are a formality. The numbers, which the market has had since May, show consolidated profit of ₹35,030 crore — up just 0.6% year-on-year. Q4 profit of ₹9,208 crore tells the same story: growth of 0.5% is noise. The board also approved the resignation of one set of secretarial auditors and the appointment of another, plus the reappointment of internal auditors. These are procedural housekeeping items. There is no new strategic or financial information in this filing.
Questions answered
- How much did Aurobindo’s profit grow in FY26?
- Consolidated profit after tax rose 0.6% year-on-year to ₹35,030 crore for the full year ended March 31, 2026. Q4 profit was ₹9,208 crore, up 0.5%.
- Why is this filing being reported now if the numbers are old?
- This is the formal board approval of the audited results, a regulatory requirement. The preliminary figures were disclosed in a press release in May 2026.
- What changed with the auditors?
- The secretarial auditors resigned and new ones were appointed. The internal auditors were reappointed. Both are routine governance steps with no stated financial impact.
- Is this filing expected to move the stock?
- Unlikely. The earnings figures were already public, and the changes are procedural. The market typically prices in results after the initial announcement.
Aurobindo Pharma Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on AUROPHARMA →- 21 May 2026 · 10:44 PM IST Aurobindo’s FY26 audited results are a formality. Profit growth is 0.6%.
- today Aurobindo gets second OAI plant in six months
- 21d ago Aurobindo sees FY27 margins topping 21% after record ₹33,653 cr revenue year
- 22d ago Aurobindo's TheraNym to build a drug plant for MSD, capex up to $175M
- 22d ago Aurobindo's FY26 revenue grows 5.6%, profit up 2%